Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hemab Therapeutics
Biotech
Hemab raises $157M series C for rare bleeding disorder goals
The company will use the funding to build out its pipeline to advance its clinical candidates for Glanzmann thrombasthenia and von Willebrand disease.
Zoey Becker
Oct 27, 2025 6:00am
Merck KGaA lands new R&D chief—Chutes & Ladders
Sep 5, 2025 8:30am
Apellis COO stepping down to take first CEO job—Chutes & Ladders
Jan 17, 2025 8:30am
Hemab uses $135M series B to target neglected blood disorders
Feb 21, 2023 4:07am
